Suppr超能文献

肌萎缩侧索硬化症患者行经皮内镜下胃造口术:对生存的影响。

Percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis: effect on survival.

机构信息

ALS Clinical Research Center, Department of Experimental Biomedicine and Clinical Neurosciences, University of Palermo, Italy.

出版信息

J Neurol Sci. 2011 May 15;304(1-2):44-8. doi: 10.1016/j.jns.2011.02.016. Epub 2011 Mar 3.

Abstract

BACKGROUND

Percutaneous endoscopic gastrostomy (PEG) is offered to amyotrophic lateral sclerosis (ALS) patients with severe dysphagia. Immediate benefits of PEG are adequate food intake and weight stabilization. However, the impact of PEG on survival is still uncertain. In this work we retrospectively evaluated the effect of PEG on survival in a cohort of ALS patients followed in a tertiary referral centre.

METHODS

Between 2000 and 2007, 150 dysphagic ALS patients were followed until death or tracheostomy. PEG was placed in 76 patients who accepted the procedure and survival was analysed using the Kaplan-Meier life-table method.

RESULTS

In ALS patients submitted to PEG, no major complications were observed. Total median survival time from symptom onset was 38 months for PEG users as compared to 32 months for the remaining dysphagic patients who declined the procedure (p=0.05). Among bulbar-onset patients, PEG users showed a median survival time longer than those with no PEG (28 months vs. 25 months), even though the difference was not significant. Conversely, dysphagic spinal-onset patients with PEG lived significantly longer than those who refused this palliative care (44 months vs. 36 months, p=0.046). Survival in patients with PEG was not affected by the severity of the respiratory impairment, as measured by forced vital capacity.

CONCLUSIONS

This study demonstrates that PEG improves survival in dysphagic ALS patients, with few side effects. The procedure is safe and applicable even to patients with impaired respiratory function. PEG remains a milestone in palliative care in dysphagic ALS patients.

摘要

背景

经皮内镜下胃造口术(PEG)用于治疗严重吞咽困难的肌萎缩侧索硬化症(ALS)患者。PEG 的即时益处是能够充分摄入食物和稳定体重。然而,PEG 对生存的影响仍不确定。在这项工作中,我们回顾性评估了 PEG 在我们的三级转诊中心随访的一组 ALS 患者中的生存影响。

方法

在 2000 年至 2007 年间,150 名吞咽困难的 ALS 患者接受了随访,直到死亡或气管切开术。76 名接受该程序的吞咽困难 ALS 患者接受了 PEG,使用 Kaplan-Meier 生命表法分析生存情况。

结果

在接受 PEG 的 ALS 患者中,未观察到重大并发症。从症状发作开始,PEG 使用者的总中位生存时间为 38 个月,而拒绝该程序的其余吞咽困难患者为 32 个月(p=0.05)。在球部起病的患者中,PEG 使用者的中位生存时间长于未行 PEG 的患者(28 个月比 25 个月),尽管差异无统计学意义。相反,拒绝这种姑息治疗的吞咽困难脊髓起病患者的生存时间明显长于拒绝者(44 个月比 36 个月,p=0.046)。PEG 对生存的影响不受用力肺活量测量的呼吸功能损害严重程度的影响。

结论

这项研究表明,PEG 可改善吞咽困难 ALS 患者的生存,且副作用少。该程序安全且适用于呼吸功能受损的患者。PEG 仍然是吞咽困难 ALS 患者姑息治疗的里程碑。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验